

Amendments to the Claims

This listing of claims will replace all prior versions and listings of claims in the application:

1. (Currently Amended) A method for inhibiting the immunological rejection of a an allogenic transplant in a subject which comprises administering to the subject, at a suitable time after transplant, a prophylactically effective an amount of streptavidin effective to inhibit such immunological rejection.
2. (Original) The method of claim 1, wherein the subject is a human.
3. (Original) The method of claim 1, wherein the transplant is an organ transplant.
4. (Original) The method of claim 1, wherein the transplant is a tissue transplant.
5. (Canceled)
6. (Canceled)
7. (Original) The method of claim 1, wherein the streptavidin is administered intraperitoneally.

8. (Original) The method of claim 7, wherein the streptavidin is administered in a dose of between about 2 mg/kg to about 200 mg/kg of subject body weight per day.
9. (Original) The method of claim 8, wherein the streptavidin is administered in a dose of between about 10 mg/kg to about 40 mg/kg of subject body weight per day.
10. (Original) The method of claim 9, wherein the streptavidin is administered in a dose of about 20 mg/kg of subject body weight per day.
11. (Original) The method of claim 1, wherein the streptavidin is administered intravenously.
12. (Original) The method of claim 11, wherein the streptavidin is administered in a dose of between about 2 mg/kg to about 200 mg/kg of subject body weight per day.
13. (Original) The method of claim 12, wherein the streptavidin is administered in a dose of between about 10 mg/kg to about 40 mg/kg of subject body weight per day.
14. (Original) The method of claim 13, wherein the streptavidin is administered in a dose of about 20 mg/kg of subject body weight per day.
15. (Original) The method of claim 1, wherein the streptavidin is administered subcutaneously.

Applicant: Rashid A. Fawwaz
U.S. Serial No.: 10/608,841
Filed: June 26, 2003
Page 6

16. (Original) The method of claim 15, wherein the streptavidin is administered in a dose of between about 2 mg/kg to about 200 mg/kg of subject body weight per day.
17. (Original) The method of claim 16, wherein the streptavidin is administered in a dose of between about 10 mg/kg to about 40 mg/kg of subject body weight per day.
18. (Original) The method of claim 17, wherein the streptavidin is administered in a dose of about 20 mg/kg of subject body weight per day.
19. (Original) The method of claim 1, further comprising the step of administering an anti-lymphocyte antibody to the subject at a suitable time.
20. (Original) The method of claim 19, wherein the anti-lymphocyte antibody is administered to the subject concurrently with streptavidin.
21. (Original) The method of claim 19, wherein the anti-lymphocyte antibody is administered to the subject at a time different from that when streptavidin is administered.
- 22-26. (Canceled)